Method of forming conductive lines

Details Method of forming conductive lines Method of forming conductive lines

2000-03-29

2002-02-12

Bawa, Raj (Department: 1619)

Drug, bio-affecting and body treating compositions

Effervescent or pressurized fluid containing

Organic pressurized fluid

C424S046000

Reexamination Certificate

active

06346232

ABSTRACT:

TECHNICAL FIELD OF THE INVENTION
This invention pertains to solution aerosol formulations suitable for use in administering drugs. In another aspect this invention pertains to formulations comprising beclomethasone 17,21 dipropionate.
BACKGROUND OF THE INVENTION
Pharmaceutical suspension aerosol formulations currently use a mixture of liquid chlorofluorocarbons as the propellant. Fluorotrichloromethane, dichlorodifluoromethane and dichlorotetrafluoroethane are the most commonly used propellants in aerosol formulations for administration by inhalation.
Chlorofluorocarbons have been implicated in the destruction of the ozone layer and their production is being phased out. Hydrofluorocarbon 134a (HFC-134a, 1,1,1,2-tetrafluoroethane) and hydrofluorocarbon 227 (HFC-227, 1,1,1,2,3,3,3-heptafluoropropane) are viewed as being less destructive to ozone than many chlorofluorocarbon propellants; furthermore, they have low toxicity and vapor pressure suitable for use in aerosols.
Beclomethasone 17,21 dipropionate is commercially available as an aerosol product comprising a suspension of a chlorofluorohydrocarbon solvate of beclomethasone 17,21 dipropionate in chlorofluorohydrocarbon propellants. Preparation of the solvate requires several processing steps and is required in order to obtain a stable aerosol formulation, i.e., one in which the micronized particles of active ingredient remain in the desired respirable particle size range. A solution formulation of beclomethasone 17,21 dipropionate could simplify formulation manufacture and increase the respirable fraction (i.e., the percentage of active ingredient able to reach the airways of the lung where the pharmaceutical effect is exerted).
U.S. Pat. No. 2,868,691 discloses a self-propelling pharmaceutical aerosol formulation comprising i) a medicament; ii) a propellant represented generally by the formula C
m
H
n
Cl
y
F
z
, wherein m is an integer less than 3, n is an integer or zero, y is an integer or zero, and z is an integer, such that n+y+z=2m+2; and iii) a cosolvent which assists in the dissolution of the medicament in the propellant. Ethanol is an example of a cosolvent disclosed in this patent. The above formula representing the propellant component generically embraces HFC-134a. This patent does not, however, disclose beclomethasone 17,21 dipropionate or suggest how stable solution aerosol formulations (i.e., formulations that are chemically stable and exhibit desirable respirable fraction) containing any propellant and beclomethasone 17,21 dipropionate can be prepared.
SUMMARY OF THE INVENTION
The present invention provides an aerosol formulation comprising a therapeutically effective amount of beclomethasone 17,21 dipropionate, a propellant comprising a hydrofluorocarbon selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof, and ethanol in an amount effective to solubilize the beclomethasone 17,21 dipropionate in the propellant, the formulation being further characterized in that substantially all of the beclomethasone 17,21 dipropionate is dissolved in the formulation, and the formulation is substantially free of any surfactant.
Certain of the preferred formulations of the invention exhibit very desirable chemical stability and provide respirable fractions significantly greater than commercially available beclomethasone 17,21 dipropionate products. Moreover, the formulations of the invention are convenient to manufacture since no solvate of the active ingredient need be prepared.
The pharmaceutical solution aerosol formulations of the invention are suitable for pulmonary, buccal, or nasal administration.


REFERENCES:
patent: 2868691 (1959-01-01), Porush et al.
patent: 2885427 (1959-05-01), Ruh
patent: 3014844 (1961-12-01), Thiel et al.
patent: 3320125 (1967-05-01), Grim
patent: 3897779 (1975-08-01), Hansen
patent: 4083954 (1978-04-01), Tsuchiya et al.
patent: 4174295 (1979-11-01), Bargigia
patent: 4243548 (1981-01-01), Heeb et al.
patent: 4352789 (1982-10-01), Thiel
patent: 4810488 (1989-03-01), Jinks
patent: 4851211 (1989-07-01), Adjei et al.
patent: 4913892 (1990-04-01), Page et al.
patent: 5118494 (1992-06-01), Schultz et al.
patent: 5202110 (1993-04-01), Dalby et al.
patent: 5225183 (1993-07-01), Purewal et al.
patent: 5290539 (1994-03-01), Marecki
patent: 5345980 (1994-09-01), Burt et al.
patent: 5439670 (1995-08-01), Purewal et al.
patent: 5474759 (1995-12-01), Fassberg et al.
patent: 5605674 (1997-02-01), Purewal et al.
patent: 5674471 (1997-10-01), Akehurst et al.
patent: 5674473 (1997-10-01), Purewal et al.
patent: 5681545 (1997-10-01), Purewal et al.
patent: 5683677 (1997-11-01), Purewal et al.
patent: 5695743 (1997-12-01), Purewal et al.
patent: 5720940 (1998-02-01), Purewal et al.
patent: 5766573 (1998-06-01), Purewal et al.
patent: 5776432 (1998-07-01), Schultz et al.
patent: 5776434 (1998-07-01), Purewal et al.
patent: 6006745 (1999-12-01), Marecki
patent: 3905726 (1990-08-01), None
patent: 172672 (1988-01-01), None
patent: 0372777 (1990-06-01), None
patent: 0384371 (1990-08-01), None
patent: 504112 (1992-09-01), None
patent: 616525 (1995-09-01), None
patent: 2001334 (1979-01-01), None
patent: H2-200627 (1990-08-01), None
patent: 86/04233 (1986-07-01), None
patent: 91/11173 (1991-08-01), None
patent: 91/11495 (1991-08-01), None
patent: 91/11496 (1991-08-01), None
patent: 92/22287 (1992-12-01), None
patent: 93/04671 (1993-09-01), None
Taisho Yakuhin Kogyo, demand for trail against Japanese patent 2769925, Aug. 28, 2000 (Osaka, Japan).
Osaka Association Hospital Pharmacists, Edited, Completely RevisedIyakuhin Youran, Yakugyou Jihou Co., Ltd, published Oct. 5, 1986, cover, explanatory notes, p. 292, and back flap.
Written Statement of Austen John Woolfe of Norton Health Care, dated Aug. 17, 2000.
Robinson, Joseph R., and Lee, Vincent H.L., “Influence of Drug Properties and Routes of Drug Administration of the Design of Sustained and Controlled Release Systems,”Controlled Drug Delivery, Fundamentals and Applications,chapter 1, pp. 3-4 and 45-47 (Mercel Dekker, Inc., New York, 1987).
Certified copy of the Test Report of the Medicines Testing Laboratory dated Aug. 3, 1999, “Report of the Results of the Twelve Month Time Point for Beclomethasone Dipropionate Inhalers Stability Study”.
Certified copy of Study Protocol Agreement for Analysis of Chemical Stability of BDP HFA MDI between Norton (Waterford) Ltd. and Medicines Testing Laboratory.
Nihon Yakkyoku Hou KaisetsushoA&OHgr;B&OHgr;C&OHgr;D&OHgr;E&OHgr;F, 10thRevised Edition, first published Jul. 25, 1981, inside cover flap, table of contents, pp. A-29, A-36, and inside flap of back cover (Hirokawa Shoten Co., Ltd., Japan).
Test report dated Aug. 17, 2000, compiled by Hideko Shigefuji of Taisho Yakuhin Kogyo). Particle sizes are measured for Beclazone 50 Inhaler (of Taisho Yakuhin) and Becotide 50 Inhaler (of Nippon Glaxo).
Campos, et al, “Beclomethasone Dipropionate in the Treatment of corticosteroid-dependent Bronchial Asthma. Comparative Study of Two Aerosol Preparations”,Pharmatherapeutica,vol. 1, No. 3, 1977, pp. 552-556.
Taisho “Reply” dated Aug. 29, 2000, In 3M v. Taisho Yakuhin Kogyo, Case No. 12 (Wa) 7221, Osaka, Japan.
Taisho “Brief 1” with exhibits B-2-B9, dated Oct. 6, 2000, in 3M v. Taisho Yakuhin Kogyo, Case No. 12 (Wa) 7221, Osaka, Japan.
Taisho “Preparatory Document (2)” with exhibits B10-B18, dated Jan. 22, 2001, 3M v. Tashio Yakuhin Kogyo, Case No. 12 (Wa) 7221, Osaka, Japan.
Taisho “Preparatory Document (3)” with exhibits B19-B22, dated Apr. 9, 2001, 3M v. Taisho Yakuhin Kogyo, Case No. 12, (Wa) 7221, Osaka, Japan.
Taisho “Description of Exhibits (4),” dated Feb. 8, 2001, 3M v. Taisho Yakuhin Kogyo, Case No. 12 (Wa) 7221, Osaka, Japan.
IVAX, et al. v. Minnesota Mining and Manufacturing Company, Complaint filed Aug. 30, 2000, Civil Action 00-3219, U.S. District Court for the Southern District of Florida.
ICI News Release, “ICI Announces ‘Ozone Friendly’ Production Plants”, dated Nov. 22, 1988 (ICI Amernicas Inc., Willmington, Delaware).
Compos, et al. “Beclo

Affiliated with

Also associated with

Rating

Method of forming conductive lines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of forming conductive lines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of forming conductive lines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2950203